Daver N et al. Targeting FLT3 mutations in AML: Review of current knowledge and evidence. Leukemia 2019;33(2):299-312. Abstract

DiNardo CD  et al. A randomized, double-blind, placebo-controlled study of venetoclax with azacitidine vs azacitidine in treatment-naïve patients with acute myeloid leukemia ineligible for intensive therapy — VIALE-A. EHA 2020;Abstract LB2601.

DiNardo CD et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383(7):617-29. Abstract

Fathi AT et al. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: Analysis of a phase 1/2 study. JAMA Oncol 2018;4(8):1106-10. Abstract

Medeiros BC et al. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia 2017;31(2):272-81. Abstract

Perl AE et al. Long-term survivors and gilteritinib safety beyond one year in FLT3-mutated R/R AML: ADMIRAL trial follow-up. ASCO 2020;Abstract 7514.

Short NJ et al. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther Adv Hematol 2019;10:2040620719827310. Abstract

Wei AH et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 2020;383(26):2526-37. Abstract

Wei AH et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial. Blood 2020;135(24):2137-45. Abstract